Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi

TÜKENMEZ TİGEN, Elif; MULAZIMOGLU, LUTFIYE

Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi

Elif TÜKENMEZ TİGEN, (İstanbul Medeniyet Üniversitesi, Göztepe Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye)

Lütfiye MÜLAZIMOĞLU (Marmara Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı,İstanbul, Türkiye)

Klimik Dergisi

3 0

Yıl: 2012 Cilt: 25 Sayı: 3 Sayfa Aralığı: 94 - 98 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi

Öz:

Toplum kökenli genişlemiş spektrumlu β-laktamaz (GSBL) üreten mikroorganizmalar hayatı tehdit edici infeksiyonlara neden olmaktadır. Bu infeksiyonların büyük çoğunluğunu CTX-M oluş- turan Escherichia colinin etken olduğu idrar yolu infeksiyonları ve buna bağlı gelişen bakteriyemiler oluşturmaktadır. Zamanında uygun tedavi başlanmadığında ciddi mortalite nedeni olabileceğinden, bu infeksiyonlara yaklaşım büyük önem ve dikkat gerektirmektedir.

Anahtar Kelime:

Konular: Mikrobiyoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Enfeksiyon Hastalıkları

Extended-Spectrum β-Lactamases and Their Clinical Importance in Community-Acquired Infections

Öz:

Community-acquired extended-spectrum β-lactamase (ESBL) producing organisms cause life threatening infections, the majority of which are urinary tract infections and bacteremias caused by CTX-M enzyme producing Escherichia coli. Approach to these infections requires great care because their mortality rates are high unless timely and appropriate treatment is started

Anahtar Kelime:

Konular: Mikrobiyoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Enfeksiyon Hastalıkları

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Rahal JJ. Extended-spectrum beta-lactamases: how big is the problem? Clin Microbiol Infect. 2000; 6(Suppl. 2): 2-6. [CrossRef]
2. Cantón R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect. 2008; 14(Suppl. 1): 144-53. [CrossRef]
3. Coque TM, Oliver A, Pérez-Díaz JC, Baquero F, Cantón R. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum betalactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother. 2002; 46(2): 500-10. [CrossRef]
4. Kang CI, Wi YM, Lee MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012; 50(2): 312-7. [CrossRef]
5. Pitout JD, Laupland KB. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008; 8(3): 159-66. [CrossRef]
6. Weyrich P, Ettahar N, Legout L, Meybeck A, Leroy O, Senneville E. First initial community-acquired meningitis due to extendedspectrum beta-lactamase producing Escherichia coli complicated with multiple aortic mycotic aneurysms. Ann Clin Microbiol Antimicrob. 2012; 11: 4. [CrossRef]
7. Chaudhuri BN, Rodrigues C, Balaji V, et al. Incidence of ESBL producers amongst Gram-negative bacilli isolated from intraabdominal infections across India (based on SMART study, 2007 data). J Assoc Physicians India. 2011; 59: 287-92.
8. Jacoby GA, Sutton L. Properties of plasmids responsible for production of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991; 35(1): 164-9. [CrossRef]
9. Novais A, Cantón R, Moreira R, Peixe L, Baquero F, Coque TM. Emergence and dissemination of Enterobacteriaceae isolates producing CTX-M-1-like enzymes in Spain are associated with IncFII (CTX-M-15) and broad-host-range (CTX-M-1, -3, and -32) plasmids. Antimicrob Agents Chemother. 2007; 51(2): 796-9. [CrossRef]
10. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004; 42(10): 4769-75. [CrossRef]
11. Mirelis B, Navarro F, Miró E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis. 2003; 9(8): 1024-5. [CrossRef]
12. Wickramasinghe NH, Xu L, Eustace A, Shabir S, Saluja T, Hawkey PM. High community faecal carriage rates of CTX-M ESBLproducing Escherichia coli in a specific population group in Birmingham, UK. J Antimicrob Chemother. 2012; 67(5): 1108-13. [CrossRef]
13. Moubareck C, Daoud Z, Hakimé NI, et al. Countrywide spread of community- and hospital-acquired extended-spectrum betalactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J Clin Microbiol. 2005; 43(7): 3309-13. [CrossRef]
14. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli-producing extendedspectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis. 2004; 38(12): 1736-41. [CrossRef]
15. Rodríguez-Baño J, López-Cerero L, Navarro MD, Díaz de Alba P, Pascual A. Faecal carriage of extended-spectrum beta-lactamaseproducing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother. 2008; 62(5): 1142-9. [CrossRef]
16. Reuland EA, Overdevest IT, Al Naiemi N, et al. High prevalence of ESBL-producing Enterobacteriaceae carriage in Dutch community patients with gastrointestinal complaints. Clin Microbiol Infect. (In Press).
17. Tukenmez Tigen E, Tandogdu Z, Ergonul O, Altinkanat G, Gunaydin B, Ozgen M. Impact of fecal carriage of extended spectrum beta lactamases (ESBL) producing Enterobacteriaceae before transrectal ultrasound guided neddle biopsy of the prostate [Abstract]. In: Abstracts of 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (Chicago, September 17-20, 2011). Washington, DC: American Society for Microbiology, 2011: L2-902.
18. Carattoli A. Animal reservoirs for extended spectrum betalactamase producers. Clin Microbiol Infect. 2008; 14(Suppl. 1): 117-23. [CrossRef]
19. Warren RE, Ensor VM, ONeill P, et al. Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother. 2008; 61(3): 504-8. [CrossRef]
20. Chiaretto G, Zavagnin P, Bettini F, et al. Extended spectrum betalactamase SHV-12-producing Salmonella from poultry. Vet Microbiol. 2008; 128(3-4): 406-13. [CrossRef]
21. Girlich D, Poirel L, Carattoli A, et al. Extended-spectrum betalactamase CTX-M-1 in Escherichia coli isolates from healthy poultry in France. Appl Environ Microbiol. 2007; 73(14): 4681-5. [CrossRef]
22. Aarestrup FM, Hasman H, Agersø Y, Jensen LB, Harksen S, Svensmark B. First description of blaCTX-M-1-carrying Escherichia coli isolates in Danish primary food production. J Antimicrob Chemother. 2006; 57(6): 1258-9. [CrossRef]
23. Sunde M, Tharaldsen H, Slettemeås JS, Norström M, Carattoli A, Bjorland J. Escherichia coli of animal origin in Norway contains a blaTEM-20-carrying plasmid closely related to blaTEM-20 and blaTEM-52 plasmids from other European countries. J Antimicrob Chemother. 2009; 63(1): 215-6. [CrossRef]
24. Riaño I, Moreno MA, Teshager T, Sáenz Y, Domínguez L, Torres C. Detection and characterization of extended-spectrum betalactamases in Salmonella enterica strains of healthy food animals in Spain. J Antimicrob Chemother. 2006; 58(4): 844-7. [CrossRef]
25. Cavaco LM, Abatih E, Aarestrup FM, Guardabassi L. Selection and persistence of CTX-M-producing Escherichia coli in the intestinal flora of pigs treated with amoxicillin, ceftiofur, or cefquinome. Antimicrob Agents Chemother. 2008; 52(10): 3612-6. [CrossRef]
26. Arslan H, Kurt Azap Ö, Turan H, Çolakoğlu Ş, Erdoğan H, Karaman S. Toplum kökenli üriner sistem infeksiyonlarından izole edilen Esherichia coli suşlarında genişlemiş spektrumlu beta laktamaz (GSBL) üretme sıklığı [Özet]. Klimik Derg. 2007; 20(Suppl. 1): 361.
27. Kart Yaşar K, Pehlivanoğlu F, Şengöz G, Bakar M. Antimicrobial resistance of 615 Escherichia coli isolated from complicated and non-complicated urinary tract infections. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2011; 31(6): 1457-62.
28. Calbo E, Romaní V, Xercavins M, et al. Risk factors for communityonset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006; 57(4): 780-3. [CrossRef]
29. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004; 23(3): 163-7. [CrossRef]
30. Siedelman L, Kline S, Duval S. Risk factors for communityand health facility-acquired extended-spectrum β-lactamaseproducing bacterial infections in patients at the University of Minnesota Medical Center, Fairview. Am J Infect Control. 2012; 40(9): 849-53. [CrossRef]
31. Demir N, Gençer S, Özer S, Doğan M. Genişlemiş spektrumlu beta-laktamaz üreten gram-negatif bakteri infeksiyonları için çeşitli risk faktörlerinin araştırılması. Flora. 2008; 13(4): 179-88.
32. Yılmaz E, Akalın H, Özbey S, et al. Genişlemiş spektrumlu betalaktamaz (GSBL) yapan Escherichia coli ve Klebsiella pneumoniae kökenleri ile gelişen toplum kökenli üriner sistem enfeksiyonlarında risk faktörleri [Özet]. Klimik Derg. 2007; 20(Suppl. 1): 276.
33. Poirel L, Leviandier C, Nordmann P. Prevalence and genetic analysis of plasmid-mediated quinolone resistance determinants QnrA and QnrS in Enterobacteriaceae isolates from a French university hospital. Antimicrob Agents Chemother. 2006; 50(12): 3992-7. [CrossRef]
34. Yan JJ, Wu JJ, Ko WC, et al. Plasmid-mediated 16S rRNA methylases conferring high-level aminoglycoside resistance in Escherichia coli and Klebsiella pneumoniae isolates from two Taiwanese hospitals. J Antimicrob Chemother. 2004; 54(6): 1007-12. [CrossRef]
35. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis. 2006; 42(7): 925-34. [CrossRef]
36. Rodríguez-Baño J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006; 43(11): 1407-14. [CrossRef]
37. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extendedspectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000; 30(3): 473-8. [CrossRef]
38. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet. 1998; 351(9105): 797-9. [CrossRef]
39. Karah N, Poirel L, Bengtsson S, et al. Plasmid-mediated quinolone resistance determinants qnr and aac(6)-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden. Diagn Microbiol Infect Dis. 2010; 66(4): 425-31. [CrossRef]
40. Yagci D, Yoruk F, Azap A, Memikoglu O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother. 2009; 53(3): 1287-9. [CrossRef]
41. Korten V, Ulusoy S, Zarakolu P, Mete B; Turkish MYSTIC Study Group. Turkish MYSTIC Study Group. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. Diagn Microbiol Infect Dis. 2007; 59(4): 453-7. [CrossRef]
42. Nazik H, Öngen B, Sarıkaya A, Kuvat N, İlktaç M. Genişlemiş spektrumlu beta-laktamaz üreten Klebsiella pneumoniae suşlarında CTX-M tipi beta-laktamaz sıklığı ve antibiyotik ko-rezistansı. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2011; 31(2): 300-6.
43. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007; 67(7): 1027-52. [CrossRef]
44. Patel JB, Rasheed JK, Kitchel B. Carbapenemases in Enterobacteriaceae: activity, epidemiology, and laboratory detection. Clin Microbiol Newsl. 2009; 31(8): 55-62. [CrossRef]
45. Aubron C, Poirel L, Ash RJ, Nordmann P. Carbapenemaseproducing Enterobacteriaceae, U.S. rivers. Emerg Infect Dis. 2005; 11(2): 260-4. [CrossRef]
46. Yigit H, Queenan AM, Rasheed JK, et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother. 2003; 47(12): 3881-9. [CrossRef]
47. Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P. Ertapenem resistance of Escherichia coli. Emerg Infect Dis. 2007; 13(2): 315-7. [CrossRef]
48. Carrër A1, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother. 2008;52(8):2950-4. [CrossRef]
49. Aktaş Z, Kayacan CB, Schneider I, Can B, Midilli K, Bauernfeind A. Carbapenem-hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy. 2008; 54(2): 101-6. [CrossRef]
50. Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. J Antimicrob Chemother. 2006; 57(3): 373-83. [CrossRef]
51. Endimiani A, Perez F, Bajaksouzian S, et al. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol. 2010; 48(12): 4417-25. [CrossRef]
52. Baylan O. Fosfomisin: dünü, bugünü ve geleceği. Mikrobiyol Bül. 2010; 44(2): 311-21.
53. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007; 29(1): 62-5. [CrossRef]
54. Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extendedspectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010; 65(11): 2459-63. [CrossRef]

APA	TÜKENMEZ TİGEN E, MULAZIMOGLU L (2012). Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. , 94 - 98.
Chicago	TÜKENMEZ TİGEN Elif,MULAZIMOGLU LUTFIYE Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. (2012): 94 - 98.
MLA	TÜKENMEZ TİGEN Elif,MULAZIMOGLU LUTFIYE Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. , 2012, ss.94 - 98.
AMA	TÜKENMEZ TİGEN E,MULAZIMOGLU L Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. . 2012; 94 - 98.
Vancouver	TÜKENMEZ TİGEN E,MULAZIMOGLU L Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. . 2012; 94 - 98.
IEEE	TÜKENMEZ TİGEN E,MULAZIMOGLU L "Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi." , ss.94 - 98, 2012.
ISNAD	TÜKENMEZ TİGEN, Elif - MULAZIMOGLU, LUTFIYE. "Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi". (2012), 94-98.

APA	TÜKENMEZ TİGEN E, MULAZIMOGLU L (2012). Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. Klimik Dergisi, 25(3), 94 - 98.
Chicago	TÜKENMEZ TİGEN Elif,MULAZIMOGLU LUTFIYE Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. Klimik Dergisi 25, no.3 (2012): 94 - 98.
MLA	TÜKENMEZ TİGEN Elif,MULAZIMOGLU LUTFIYE Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. Klimik Dergisi, vol.25, no.3, 2012, ss.94 - 98.
AMA	TÜKENMEZ TİGEN E,MULAZIMOGLU L Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. Klimik Dergisi. 2012; 25(3): 94 - 98.
Vancouver	TÜKENMEZ TİGEN E,MULAZIMOGLU L Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi. Klimik Dergisi. 2012; 25(3): 94 - 98.
IEEE	TÜKENMEZ TİGEN E,MULAZIMOGLU L "Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi." Klimik Dergisi, 25, ss.94 - 98, 2012.
ISNAD	TÜKENMEZ TİGEN, Elif - MULAZIMOGLU, LUTFIYE. "Toplum Kökenli İnfeksiyonlarda Genişlemiş Spektrumlu β-Laktamazlar ve Klinik Önemi". Klimik Dergisi 25/3 (2012), 94-98.